Hidehisa Iwata

1.8k total citations
44 papers, 1.4k citations indexed

About

Hidehisa Iwata is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Hidehisa Iwata has authored 44 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 16 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Hidehisa Iwata's work include HER2/EGFR in Cancer Research (9 papers), Angiogenesis and VEGF in Cancer (7 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Hidehisa Iwata is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Angiogenesis and VEGF in Cancer (7 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Hidehisa Iwata collaborates with scholars based in Japan, United States and Nigeria. Hidehisa Iwata's co-authors include Hiroshi Miki, Akira Hori, Shinichi Imamura, Terufumi Takagi, Shigeyuki Mori, Naoki Miyamoto, Osamu Sano, Satoshi Sogabe, Tomoyasu Ishikawa and Yuya Oguro and has published in prestigious journals such as Nature Communications, PLoS ONE and Biochemistry.

In The Last Decade

Hidehisa Iwata

44 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hidehisa Iwata Japan 22 683 351 277 133 124 44 1.4k
Robert A. Mook United States 24 1.2k 1.7× 337 1.0× 369 1.3× 59 0.4× 123 1.0× 38 1.9k
Ramasamy Sakthivel India 22 616 0.9× 216 0.6× 141 0.5× 78 0.6× 153 1.2× 50 1.3k
Jung‐Mo Ahn United States 26 1.1k 1.7× 317 0.9× 255 0.9× 73 0.5× 259 2.1× 63 2.1k
Douglas W. Morgan United States 24 683 1.0× 166 0.5× 273 1.0× 188 1.4× 161 1.3× 53 1.4k
Jeffrey P. Krise United States 24 802 1.2× 241 0.7× 248 0.9× 234 1.8× 69 0.6× 37 1.6k
Roman Mezencev United States 29 1.1k 1.6× 238 0.7× 472 1.7× 97 0.7× 132 1.1× 86 2.4k
Koichi Kawasaki Japan 22 851 1.2× 261 0.7× 155 0.6× 116 0.9× 143 1.2× 130 1.9k
Sheng Jiang China 27 1.2k 1.7× 475 1.4× 307 1.1× 71 0.5× 59 0.5× 77 2.1k
Alexander Kaplun Russia 21 780 1.1× 112 0.3× 190 0.7× 96 0.7× 73 0.6× 96 1.4k

Countries citing papers authored by Hidehisa Iwata

Since Specialization
Citations

This map shows the geographic impact of Hidehisa Iwata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidehisa Iwata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidehisa Iwata more than expected).

Fields of papers citing papers by Hidehisa Iwata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidehisa Iwata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidehisa Iwata. The network helps show where Hidehisa Iwata may publish in the future.

Co-authorship network of co-authors of Hidehisa Iwata

This figure shows the co-authorship network connecting the top 25 collaborators of Hidehisa Iwata. A scholar is included among the top collaborators of Hidehisa Iwata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hidehisa Iwata. Hidehisa Iwata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nagai, Hiroaki, et al.. (2024). Direct conversion of urine-derived cells into functional motor neuron-like cells by defined transcription factors. Scientific Reports. 14(1). 27011–27011. 1 indexed citations
2.
Ito, Masahiro, et al.. (2023). Novel quinazolin-4(3H)-one based Cyclin K degraders regulate alternative polyadenylation activity. Biochemical and Biophysical Research Communications. 676. 6–12. 4 indexed citations
3.
Wakita, Masahiro, Akiko Takahashi, Osamu Sano, et al.. (2020). A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells. Nature Communications. 11(1). 1935–1935. 157 indexed citations
4.
Balakrishna, Deepika, Shweta Pandya, Mark S. Hixon, et al.. (2017). MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody. Molecular Cancer Therapeutics. 16(7). 1269–1278. 11 indexed citations
5.
6.
Sano, Osamu, et al.. (2016). Tubulin is a molecular target of the Wnt-activating chemical probe. BMC Biochemistry. 17(1). 9–9. 12 indexed citations
7.
Nakamura, Kazuhide, Akio Mizutani, Hidehisa Iwata, et al.. (2013). A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities. Molecular Cancer Therapeutics. 12(6). 913–924. 27 indexed citations
8.
9.
Oguro, Yuya, Douglas R. Cary, Naoki Miyamoto, et al.. (2013). Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: Discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics. Bioorganic & Medicinal Chemistry. 21(15). 4714–4729. 38 indexed citations
10.
Miyamoto, Naoki, Nozomu Sakai, Takaharu Hirayama, et al.. (2013). Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorganic & Medicinal Chemistry. 21(8). 2333–2345. 64 indexed citations
11.
Tomita, Naoki, Yoko Hayashi, Yoshio Aramaki, et al.. (2013). Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorganic & Medicinal Chemistry Letters. 23(6). 1779–1785. 45 indexed citations
12.
Matsumoto, Shigemitsu, Naoki Miyamoto, Takaharu Hirayama, et al.. (2013). Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors. Bioorganic & Medicinal Chemistry. 21(24). 7686–7698. 48 indexed citations
13.
Kawakita, Youichi, Masaki Seto, Tomohiro Ohashi, et al.. (2013). Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorganic & Medicinal Chemistry. 21(8). 2250–2261. 62 indexed citations
14.
Iwatani, Misa, Hidehisa Iwata, R.J. Skene, et al.. (2012). Discovery and characterization of novel allosteric FAK inhibitors. European Journal of Medicinal Chemistry. 61. 49–60. 42 indexed citations
15.
16.
Iwata, Hidehisa, Hideyuki Oki, Kengo Okada, et al.. (2012). A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases. ACS Medicinal Chemistry Letters. 3(4). 342–346. 25 indexed citations
17.
Miyamoto, Naoki, Yuya Oguro, Terufumi Takagi, et al.. (2012). Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors. Bioorganic & Medicinal Chemistry. 20(24). 7051–7058. 19 indexed citations
18.
Oguro, Yuya, Naoki Miyamoto, Kengo Okada, et al.. (2010). Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorganic & Medicinal Chemistry. 18(20). 7260–7273. 95 indexed citations
19.
Okada, Masahiro, Isao Satō, Soo‐Jeong Cho, et al.. (2005). Structure of the Bacillus subtilis quorum-sensing peptide pheromone ComX. Nature Chemical Biology. 1(1). 23–24. 124 indexed citations
20.
Hori, Hirokazu, et al.. (1997). Direct detection of evanescent electromagnetic waves at a planar dielectric surface by laser atomic spectroscopy. Physical Review A. 55(3). 2406–2412. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert A. Mook Breakdown of academic impact, for papers by Ramasamy Sakthivel Breakdown of academic impact, for papers by Jung‐Mo Ahn Breakdown of academic impact, for papers by Douglas W. Morgan Breakdown of academic impact, for papers by Jeffrey P. Krise Breakdown of academic impact, for papers by Roman Mezencev Breakdown of academic impact, for papers by Koichi Kawasaki Breakdown of academic impact, for papers by Sheng Jiang Breakdown of academic impact, for papers by Alexander Kaplun
Rankless by CCL
2026